

MAY - 2 2003

1.4 510(K) Summary

(Page 1 of 2)

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

510(k) Number K031297

Date Prepared: April 22, 2003

<i>Submitter</i>	<i>Contact Person</i>
Beckman Coulter, Inc 1000 Lake Hazeltine Drive Chaska, MN 55318	Lynn Weist Staff Regulatory Affairs Specialist Phone: 952-368-1271 Fax: 952-368-7710

General Information

Proprietary Name	Access® OV Monitor Assay
Classification Name	Tumor Associated Antigen Immunological Test System
Device Class	Class II
Legally Marketed (Unmodified) Device	Access OV Monitor Assay (K023597, cleared 12/11/02)

Device Description

The Access® OV Monitor reagents, calibrators and the Access Immunoassay Systems family comprise the Access Immunoassay System for the quantitative determination of CA 125 antigen in human serum and plasma.

Intended Use

The Access OV Monitor assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of CA 125 antigen levels in human serum and plasma, using the Access Immunoassay Systems. This device is indicated for use in the measurement of CA 125 antigen to aid in the management of ovarian cancer patients. Serial testing for patient CA 125 antigen concentrations should be used in conjunction with other clinical methods used for monitoring ovarian cancer.

510(k) Summary

(Page 2 of 2)

Description of the Modification to the Legally Marketed Device

The modification to the Access OV Monitor assay is to add a new instrument platform, the Beckman Coulter UniCel™ Dxl 800 Access® Immunoassay System, to the family of Access Immunoassay Systems. The Dxl System is a new model within the same model series of Access Immunoassay Systems manufactured and distributed by Beckman Coulter, Inc. The Dxl System was cleared for marketing by FDA on January 28, 2003, (K023764).

The Dxl uses the same Access OV Monitor reagents and calibrators, packaged the same as for the Access 2 System. The formulations of the substrate and wash buffer used with the Access OV Monitor assay are unchanged. There are no changes to the intended uses, technical specifications or final performance specifications and claims for the assay.

Supporting Data

In order to demonstrate that the Access OV Monitor assay on the Dxl system is substantially equivalent to the Access OV Monitor assay on the Access 2 system, method comparison, precision and analytical sensitivity studies were conducted. The Access OV Monitor assay met the established acceptance criteria for method comparison, precision and analytical sensitivity.

Conclusion

The information provided in this submission supports a substantial equivalence determination, and therefore, 510(k) premarket notification clearance of the Access OV Monitor assay on the UniCel Dxl 800 Access Immunoassay System.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Lynn Weist
Staff Regulatory Affairs Specialist
Beckman Coulter, Inc.
1000 Lake Hazeltine Drive
Chaska, Minnesota 55318-1084

MAY - 2 2003

Re: k031297
Trade/Device Name: Access® OV Monitor Assay
Regulation Number: 21 CFR § 866.6010
Regulation Name: Tumor associated antigen immunological test system
Regulatory Class: II
Product Code: LTK
Dated: April 23, 2003
Received: April 24, 2003

Dear Ms. Weist:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 –

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.

Director

Office of In Vitro Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

1.3 Indications for Use Statement

510(k) Number (if known): K031297

PAGE 1 OF 1

Device Name: Access® OV Monitor Assay

Indications for Use:

The Access OV Monitor assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of CA 125 antigen levels in human serum and plasma, using the Access Immunoassay Systems. This device is indicated for use in the measurement of CA 125 antigen to aid in the management of ovarian cancer patients. Serial testing for patient CA 125 antigen concentrations should be used in conjunction with other clinical methods used for monitoring ovarian cancer.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓
(per 21 CFR 801.109)

OR

Over-the-Counter Use _____
(Optional Format 1-2-96)

J. J. Reeves for J. Bantiato
(Division Sign-Off)
Division of Clinical Laboratory Devices

510(k) Number K031297